Added to YB: 2026-10-09
Pitch date: 2026-10-05
QURE [bullish]
uniQure N.V.
-2.17%
current return
Author Info
No bio for this author
Company Info
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Market Cap
$1.6B
Pitch Price
$23.02
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.50
P/E
-5.71
EV/Sales
71.84
Sector
Biotechnology
Category
special_situation
The Monday Morning Briefing: AI Drives Everything, Yet ROI on Massive Capex Remains Uncertain - uniQure N.V.
QURE (update): uniQure’s AMT-130 selloff may overstate the four-year efficacy concern: although high-dose cUHDRS slowing fell to 44% and lost significance, TFC still showed 61% slowing (nominal p=0.008), while at 48 months high-dose completers declined about 0.9 cUHDRS points versus 1.9 for low dose. The 36-month data remain the potential accelerated-approval basis; small-cohort volatility and discordant CSF NfL are risks, with Q-Motor and imaging the next evidence.
Read full article (1 min)